risperidone has been researched along with Fatty Liver in 4 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on a 17-year-old girl who developed steatohepatitis and marked weight gain during risperidone treatment for paranoid psychosis." | 5.10 | Risperidone-associated steatohepatitis and excessive weight-gain. ( Bechtinger, E; Holtmann, M; Kopf, D; Mayer, M; Schmidt, MH, 2003) |
| "Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice." | 1.48 | Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice. ( Auger, F; Bailleul, F; Bordet, R; Duriez, P; Hennebelle, T; Martin, F; Pétrault, O; Samaillie, J; Staels, B; Trabelsi, MS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auger, F | 1 |
| Martin, F | 1 |
| Pétrault, O | 1 |
| Samaillie, J | 1 |
| Hennebelle, T | 1 |
| Trabelsi, MS | 1 |
| Bailleul, F | 1 |
| Staels, B | 1 |
| Bordet, R | 1 |
| Duriez, P | 1 |
| McNamara, RK | 1 |
| Magrisso, IJ | 1 |
| Hofacer, R | 1 |
| Jandacek, R | 1 |
| Rider, T | 1 |
| Tso, P | 1 |
| Benoit, SC | 1 |
| Holtmann, M | 1 |
| Kopf, D | 1 |
| Mayer, M | 1 |
| Bechtinger, E | 1 |
| Schmidt, MH | 1 |
| Landau, J | 1 |
| Martin, A | 1 |
1 trial available for risperidone and Fatty Liver
| Article | Year |
|---|---|
Risperidone-associated steatohepatitis and excessive weight-gain.
Topics: Adolescent; Antipsychotic Agents; Fatty Liver; Female; Humans; Paranoid Disorders; Risperidone; Weig | 2003 |
3 other studies available for risperidone and Fatty Liver
| Article | Year |
|---|---|
Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice.
Topics: Animals; Blood Glucose; Curcuma; Curcumin; Fatty Liver; Female; Lipid Metabolism; Liver; Mice, Inbre | 2018 |
Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Diet; Eating; Fatty Acids, Omega-3; Fatty Liver; Gene | 2012 |
Is liver function monitoring warranted during risperidone treatment?
Topics: Adolescent; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Child; Dose-Response Relat | 1998 |